[A17-63] Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V
Last updated 01.03.2018
Project no.:
A17-63
Commission:
Commission awarded on 01.12.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Adults with moderate to severe atopic dermatitis who are candidates for systemic treatment
Indication of a non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2018-05-17 A G-BA decision was published.